See more : Nanjing Quanxin Cable Technology Co., Ltd. (300447.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Amylyx Pharmaceuticals, Inc. (AMLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amylyx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Digital Transformation Opportunities Corp. (DTOCU) Income Statement Analysis – Financial Results
- Seoul Broadcasting System (034120.KS) Income Statement Analysis – Financial Results
- HK Battery Technology, Inc. (HKBT) Income Statement Analysis – Financial Results
- Lear Corporation (0JTQ.L) Income Statement Analysis – Financial Results
- Zignago Vetro S.p.A. (0NNC.L) Income Statement Analysis – Financial Results
Amylyx Pharmaceuticals, Inc. (AMLX)
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 380.79M | 22.23M | 285.00K | 650.00K | 1.43M |
| Cost of Revenue | 25.44M | 2.99M | 52.00K | 24.59M | 11.90M |
| Gross Profit | 355.35M | 19.24M | 233.00K | -23.94M | -10.47M |
| Gross Profit Ratio | 93.32% | 86.54% | 81.75% | -3,683.69% | -734.43% |
| Research & Development | 128.19M | 93.45M | 44.04M | 24.59M | 11.90M |
| General & Administrative | 178.86M | 127.13M | 38.93M | 15.06M | 3.08M |
| Selling & Marketing | 9.50M | 4.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 188.36M | 127.13M | 38.93M | 15.06M | 3.08M |
| Other Expenses | 0.00 | 3.74M | -285.00K | -650.00K | -1.43M |
| Operating Expenses | 316.54M | 220.58M | 82.69M | 39.01M | 13.55M |
| Cost & Expenses | 341.98M | 223.57M | 82.69M | 39.01M | 13.55M |
| Interest Income | 16.16M | 4.29M | 36.00K | 14.00K | 176.00K |
| Interest Expense | 0.00 | 4.29M | 0.00 | 2.29M | 1.28M |
| Depreciation & Amortization | 1.09M | 487.00K | 52.00K | 1.00K | 13.55M |
| EBITDA | 39.89M | -200.85M | -82.64M | -39.00M | 1.11M |
| EBITDA Ratio | 10.48% | -905.72% | -29,013.33% | -5,957.08% | -938.22% |
| Operating Income | 38.80M | -201.34M | -82.69M | -39.01M | -13.55M |
| Operating Income Ratio | 10.19% | -905.72% | -29,013.33% | -6,000.77% | -950.49% |
| Total Other Income/Expenses | 15.50M | 3.74M | -5.24M | -3.28M | -162.00K |
| Income Before Tax | 54.30M | -197.60M | -87.93M | -42.28M | -13.72M |
| Income Before Tax Ratio | 14.26% | -888.89% | -30,852.98% | -6,504.62% | -961.85% |
| Income Tax Expense | 5.03M | 774.00K | -52.00K | 2.56M | 1.10M |
| Net Income | 49.27M | -198.38M | -87.88M | -44.84M | -14.82M |
| Net Income Ratio | 12.94% | -892.38% | -30,834.74% | -6,898.00% | -1,038.99% |
| EPS | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| EPS Diluted | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| Weighted Avg Shares Out | 67.23M | 66.51M | 57.86M | 56.47M | 56.47M |
| Weighted Avg Shares Out (Dil) | 69.99M | 66.51M | 57.86M | 56.47M | 56.47M |
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / April 1, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / April 1, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX
NEW YORK, NY / ACCESSWIRE / April 1, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit
LOS ANGELES , April 1, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX).
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
NEW YORK, NY / ACCESSWIRE / April 1, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
NEW YORK, NY / ACCESSWIRE / April 1, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
NEW YORK, NY / ACCESSWIRE / April 1, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ: AMLX) for violations of...
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX
NEW YORK, April 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ: AMLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of...
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX
NEW YORK, NY / ACCESSWIRE / April 1, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Source: https://incomestatements.info
Category: Stock Reports